How Edwards Lifesciences Is Breaking Barriers in Valve Replacement with M3 & EVOQUE! 

Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion, which indicates an 8% growth. This growth reflects the company’s continued commitment to innovation in the field of structural heart disease, bolstered by its diverse product portfolio. The Transcatheter Aortic Valve Replacement (TAVR) segment, with sales of $1.05 billion, experienced growth of 5.4% year-over-year. This performance exceeded expectations, largely driven by the adoption of the SAPIEN technology. Despite some pressure from competitive forces in certain regions like Japan, the company remains optimistic due to the upcoming indication approval for early TAVR trials, expected in the second quarter. The potential for further expansion in treating patients with moderate aortic stenosis (AS) also presents a long-term growth opportunity.